South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway
"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are currently underway here.
Search results for "product approval"
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines Agency for CT-P55, a biosimilar...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms
Samsung Biologics reported second-quarter revenue in the 1.3 trillion won range this year, a 30% increase from the same...
Biogen Korea Taps Pharma Veteran Kim Chul-woong as New Country Lead
Biogen Korea has appointed Kim Chul-woong as its new general manager, tapping an executive with extensive expertise in...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Shifting the Burden: Why South Korea’s OB-GYNs Reject 'Discretion' on Abortion Pills
The South Korean government's proposal to leave the prescription of abortion medication up to the professional...
Anchoring the U.S. Supply Chain: GC Green Cross Expands 30-Year Cytiva Partnership to Secure Alyglo Production
GC Green Cross has secured priority access to critical manufacturing consumables to stabilize the production of Alyglo,...
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68
Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...
Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch
Daewoong Pharmaceutical announced on the 13th that its flagship botulinum toxin product, Nabota, surpassed 1 trillion...